Bladder Wall Thickness in Symptomatic Urinary Stress Incontinence and Its Correlation with Urodynamics Results
BWT-IUS
1 other identifier
observational
60
0 countries
N/A
Brief Summary
This clinical study aims to assess the utility of ultrasonographic bladder wall thickness (BWT) measurement in patients suffering from symptomatic stress urinary incontinence (SUI). SUI is a condition characterized by involuntary leakage of urine during activities that increase intra-abdominal pressure and represents a very frequent disorder impacting women's quality of life. To diagnose SUI more accurately and especially before surgical treatment, patients undergo invasive urodynamic examination. This examination allows us to objectify the presence of any bladder dysfunction and, in particular, to evaluate the presence of detrusor overactivity. Detrusor overactivity is defined as any occurrence of detrusor contraction(s) during filing cystometry. These contractions, which may be spontaneous or provoked, produce a waveform on the cystogram, of variable duration and amplitude and may cause or not urgency symptoms. In absence of any urodynamic detrusor overactivity, the patient may be diagnosed with pure SUI. This is essential to assess before surgical treatment to avoid worsening of symptoms and to decide whether to treat the patient with concomitant pharmacological treatment. On the contrary, ultrasonography offers a non-invasive and accessible approach to evaluate bladder function. This study will involve a cohort of patients with SUI, who will undergo ultrasonographic assessment of BWT and preoperative urodynamic assessment. The objective is to determine whether BWT correlates with the urodynamics results and whether it can predict the presence or absence of detrusor overactivity and confirm the pure stress urinary incontinence
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 13, 2024
CompletedFirst Posted
Study publicly available on registry
December 18, 2024
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2026
CompletedDecember 18, 2024
December 1, 2024
1.1 years
December 13, 2024
December 17, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Bladder wall thickness in millimeters (mm) in two different bladder points (dome and trigone) in patients with or without detrusor overactivity at urodynamic assessment
From enrollment to the urodynamic examination that will be performed with 6 months from baseline visit
Eligibility Criteria
Patients with pure or prevalent stress urinary incontinence who undergo invasive urodynamic examination
You may qualify if:
- Participant is willing and able to give informed consent for participation in the study.
- Women aged \> 18 y.o.
- Women symptomatic for pure or predominant stress incontinence attending the urogynecology outpatient clinic at our institution.
- Patients undergoing urogynecological standard evaluation for their symptoms, including outpatient gynecological visit and a transvaginal ultrasound.
- Patients undergoing invasive urodynamic examination for objective assessment of their symptoms or in preparation for possible anti-incontinence surgery.
You may not qualify if:
- Patients with pure or predominant OAB symptomatology
- Current use of antimuscarinic agents or beta3-agonists (for example Mirabegron)
- Presence of urological or gynecological cancer.
- Patients with previous anti-incontinence surgery.
- Patients with pelvic organ prolapse \> II stage.
- Patients with chronic bladder retention.
- Patients with neurological diseases that may affect bladder function and urodynamic results.
- Participants unwilling or unable to give informed consent for participation in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 13, 2024
First Posted
December 18, 2024
Study Start
January 1, 2025
Primary Completion
February 1, 2026
Study Completion
February 1, 2026
Last Updated
December 18, 2024
Record last verified: 2024-12